Twist Bioscience and Astellas have entered into a research collaboration and exclusive option license agreement to identify potential therapeutic antibodies which would help to reduce tumor microenvironment-mediated immunosuppression.
AbbVie exercised an exclusive right to acquire TeneoOne, an affiliate of TeneoBio, and the company’s lead asset TNB-383B for relapsed or refractory multiple myeloma (R/R MM).
Nanobiotix is developing a way for the company’s locally injected radioenhancer for solid tumors to treat metastasized cancers, in combination with checkpoint inhibitors, and also deliver results distally.
San Diego-based Janux Therapeutics forged a strategic collaboration with pharma giant Merck potentially worth more than $1 billion to develop next-generation T cell engager immunotherapies for the treatment of cancer.
Bay Area-based CytomX and Astellas forged a strategic relationship worth up to more than $1.6 billion to discover and develop novel T-cell engaging bispecific antibodies targeting CD3 and tumor cell surface antigens for the treatment of cancer.
Yale University researchers developed a new system dubbed Multiplexed Activation of Endogenous Genes as Immunotherapy (MAEGI) that hunts down cancer cells.
Bayer struck a collaboration deal with Roche’s Foundation Medicine Inc. to develop test kits for genetic sequencing of tumor cells to identify cancer patients that benefit from Bayer’s Vitrakvi drug.
The Food and Drug Administration approved Merck & Co.’s cancer therapy Keytruda as part of a combination therapy for previously untreated patients with the most common type of kidney cancer.
The European Commission approved Bristol-Myers Squibb’s Opdivo (nivolumab) for the adjuvant treatment of adult patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.